Y
ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Cardiology · J Am Coll Cardiol · 2026-09-29

The 2026 AHA/ACC multisociety guideline on perioperative cardiovascular evaluation and management of adults having noncardiac surgery replaces the 2014 guideline, updating recommendations with new evidence on drug therapy, perioperative monitoring and devices.

Guideline
Thompson et al. 2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Cardiology · Circulation · 2026-08-18

In a prespecified secondary analysis of SELECT (17,604 adults with CVD and overweight/obesity, no diabetes), semaglutide cut hsCRP by 37.8% at 104 weeks, including without weight loss, and cut MACE vs placebo across hsCRP subgroups. Higher baseline hsCRP predicted MACE.

Secondary analysisn = 17,604
Plutzky et al. Effect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis

Sign in to react

Enter your email and we send a one-time link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.